Patrizia Pontisso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8175796/publications.pdf

Version: 2024-02-01

215 papers	8,837 citations	47409 49 h-index	60403 85 g-index
224 all docs	224 docs citations	224 times ranked	6065 citing authors

#	Article	IF	Citations
1	The proteaseâ€inhibitor SerpinB3 as a critical modulator of the stemâ€like subset in human cholangiocarcinoma. Liver International, 2022, 42, 233-248.	1.9	15
2	Hepatocyte-Specific Deletion of HIF2Î± Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 459-482.	2.3	13
3	Oncostatin <scp>M</scp> is overexpressed in <scp>NASH</scp>â€related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis. Journal of Pathology, 2022, 257, 82-95.	2.1	12
4	Hyaluronated and PEGylated Liposomes as a Potential Drug-Delivery Strategy to Specifically Target Liver Cancer and Inflammatory Cells. Molecules, 2022, 27, 1062.	1.7	14
5	Natural history of acute kidney disease in patients with cirrhosis. Journal of Hepatology, 2021, 74, 578-583.	1.8	32
6	Low P66shc with High SerpinB3 Levels Favors Necroptosis and Better Survival in Hepatocellular Carcinoma. Biology, 2021, 10, 363.	1.3	7
7	Engineered EVs for Oxidative Stress Protection. Pharmaceuticals, 2021, 14, 703.	1.7	1
8	Coronary artery calcium on standard chest computed tomography predicts cardiovascular events after liver transplantation. International Journal of Cardiology, 2021, 339, 219-224.	0.8	8
9	Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients. World Journal of Gastroenterology, 2021, 27, 8343-8356.	1.4	1
10	Hyperdynamic circulatory syndrome in a mouse model transgenic for SerpinB3. Annals of Hepatology, 2020, 19, 36-43.	0.6	1
11	PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. Journal of Clinical Medicine, 2020, 9, 3134.	1.0	19
12	Labelled micelles for the delivery of cytotoxic Cu(II) and Ru(III) compounds in the treatment of aggressive orphan cancers: Design and biological in vitro data. Journal of Inorganic Biochemistry, 2020, 213, 111259.	1.5	10
13	Le complexe antigÃ¨ne de carcinome Ã cellules squameuses-IgM (SCCA-IgM) est associÃ© Ã la pneumopathie interstitielle diffuse dans la sclÃ©rodermie systÃ©mique. Revue Du Rhumatisme (Edition Francaise), 2020, 87, 472-476.	0.0	0
14	Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. Cancer Biomarkers, 2020, 29, 189-196.	0.8	17
15	Squamous cell carcinoma antigen-IgM (SCCA-IgM) is associated with interstitial lung disease in systemic sclerosis. Joint Bone Spine, 2020, 87, 331-335.	0.8	7
16	PreS1 peptide-functionalized gold nanostructures with SERRS tags for efficient liver cancer cell targeting. Materials Science and Engineering C, 2019, 103, 109762.	3.8	17
17	Squamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity. Cancer Science, 2019, 110, 1552-1563.	1.7	21
18	MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. Journal of Clinical Medicine, 2019, 8, 171.	1.0	37

#	Article	IF	Citations
19	THU0224â€...THE HEPATITIS VIRUS PRES1 PROTEIN RETARDS THE ONSET OF LUPUS-LIKE GLOMERULONEPHRITIS IN NZB/W F1 MICE. , 2019, , .		0
20	Au(iii)-Proline derivatives exhibiting selective antiproliferative activity against HepG2/SB3 apoptosis-resistant cancer cells. Dalton Transactions, 2019, 48, 16017-16025.	1.6	5
21	Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis. Scientific Reports, 2019, 9, 20126.	1.6	6
22	SerpinB3 Differently Up-Regulates Hypoxia Inducible Factors -1Î± and -2Î± in Hepatocellular Carcinoma: Mechanisms Revealing Novel Potential Therapeutic Targets. Cancers, 2019, 11, 1933.	1.7	22
23	Characterization of SCCA-IgM as a biomarker of liver disease in an Asian cohort of patients. Scandinavian Journal of Clinical and Laboratory Investigation, 2018, 78, 204-210.	0.6	3
24	Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues: comparison between tenofovir and entecavir. European Journal of Gastroenterology and Hepatology, 2018, 30, 284-290.	0.8	9
25	Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers. Cancer Biomarkers, 2018, 21, 603-612.	0.8	24
26	Development of a novel diagnostic algorithm to predict NASH in HCV-positive patients. International Journal of Biological Markers, 2018, 33, 231-236.	0.7	3
27	SerpinB3 induces dipeptidyl-peptidase IV/CD26 expression and its metabolic effects in hepatocellular carcinoma. Life Sciences, 2018, 200, 134-141.	2.0	8
28	Serpinb3 is Overexpressed in the Liver in Presence of Iron Overload. Journal of Investigative Medicine, 2018, 66, 32-38.	0.7	2
29	Synthesis, chemical characterization and cancer cell growth-inhibitory activities of Cu(ii) and Ru(iii) aliphatic and aromatic dithiocarbamato complexes. Dalton Transactions, 2018, 47, 15477-15486.	1.6	22
30	SERPINB3 Delays Glomerulonephritis and Attenuates the Lupus-Like Disease in Lupus Murine Models by Inducing a More Tolerogenic Immune Phenotype. Frontiers in Immunology, 2018, 9, 2081.	2.2	7
31	Re-programming pullulan for targeting and controlled release of doxorubicin to the hepatocellular carcinoma cells. European Journal of Pharmaceutical Sciences, 2017, 103, 104-115.	1.9	29
32	Hospitalizations Due to Cirrhosis: Clinical Aspects in a Large Cohort of Italian Patients and Cost Analysis Report. Digestive Diseases, 2017, 35, 433-438.	0.8	34
33	Molecular Mechanisms Leading to Splanchnic Vasodilation in Liver Cirrhosis. Journal of Vascular Research, 2017, 54, 92-99.	0.6	33
34	New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. Journal of Controlled Release, 2017, 268, 184-197.	4.8	33
35	SerpinB3 Promotes Pro-fibrogenic Responses in Activated Hepatic Stellate Cells. Scientific Reports, 2017, 7, 3420.	1.6	23
36	Binding and Uptake into Human Hepatocellular Carcinoma Cells of Peptide-Functionalized Gold Nanoparticles. Bioconjugate Chemistry, 2017, 28, 222-229.	1.8	25

#	Article	IF	Citations
37	Occult liver disease burden: Analysis from a large general practitionersâ€™ database. United European Gastroenterology Journal, 2017, 5, 982-986.	1.6	12
38	SerpinB3 upregulates the Cyclooxygenase-2 / Î²-Catenin positive loop in colorectal cancer. Oncotarget, 2017, 8, 15732-15743.	0.8	15
39	Squamous cell carcinoma antigen (SCCA) is up-regulated during Barrettâ€™s carcinogenesis and predicts esophageal adenocarcinoma resistance to neoadjuvant chemotherapy. Oncotarget, 2017, 8, 24372-24379.	0.8	10
40	Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as Biomarker in Liver Disease: Biological Aspects and Clinical Applications. Biomarkers in Disease, 2017, , 559-580.	0.0	0
41	SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity. Scientific Reports, 2016, 5, 17701.	1.6	31
42	Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as Biomarker in Liver Disease: Biological Aspects and Clinical Applications. Exposure and Health, 2016, , 1-22.	2.8	0
43	FRI0245â€…SCCA-IGM Is Up-Regulated in Scleroderma Patients with Reduced DLCO: A New Biomarker of Pulmonary Involvement?. Annals of the Rheumatic Diseases, 2016, 75, 522.2-522.	0.5	0
44	AISF position paper on liver transplantation and pregnancy. Digestive and Liver Disease, 2016, 48, 860-868.	0.4	20
45	Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut, 2016, 65, 861-869.	6.1	207
46	Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study. Digestive and Liver Disease, 2016, 48, 197-202.	0.4	14
47	Benign mesothelial cells in lymph nodes and lymphatic spaces associated with ascites. Histology and Histopathology, 2016, 31, 747-50.	0.5	3
48	<scp>HCV</scp> genotype 3 and squamous cell carcinoma antigen (<scp>SCCA</scp>)â€IgM are independently associated with histological features of <scp>NASH</scp> in <scp>HCV</scp>â€infected patients. Journal of Viral Hepatitis, 2015, 22, 800-808.	1.0	12
49	SERPINB3 (Serpin Peptidase Inhibitor, Clade B (Ovalbumin), Member 3). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2015, 19, 202-209.	0.1	15
50	Hypoxia up-regulates SERPINB3 through HIF-2Î± in human liver cancer cells. Oncotarget, 2015, 6, 2206-2221.	0.8	59
51	Changes in gene expression of cytochrome P-450 in liver, kidney and aorta of cirrhotic rats. Prostaglandins and Other Lipid Mediators, 2015, 120, 134-138.	1.0	4
52	Analytical validation of a Biochip prototype for integrated analysis of AFP-IgM and SCCA-IgM serum biomarkers in patients with liver cirrhosis and hepatocellular carcinoma. Analytical Methods, 2015, 7, 629-637.	1.3	5
53	Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C. World Journal of Hepatology, 2015, 7, 2913.	0.8	4
54	Role of SERPINB3 in hepatocellular carcinoma. Annals of Hepatology, 2014, 13, 722-727.	0.6	29

#	Article	IF	Citations
55	Detection of high levels of <scp>S</scp>urvivinâ€“immunoglobulin <scp>M</scp> immune complex in sera from hepatitis <scp>C</scp> virus infected patients with cirrhosis. Hepatology Research, 2014, 44, 1008-1018.	1.8	4
56	Diagnostic and prognostic role of <scp>SCCA</scp>â€<scp>IgM</scp> serum levels in hepatocellular carcinoma (<scp>HCC</scp>). Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1637-1644.	1.4	44
57	MicroRNAs and SerpinB3 in hepatocellular carcinoma. Life Sciences, 2014, 100, 9-17.	2.0	15
58	Hepatic progenitor cells express SerpinB3. BMC Cell Biology, 2014, 15, 5.	3.0	23
59	SERPINB3 is associated with TGF-Î²1 and cytoplasmic Î²-catenin expression in hepatocellular carcinomas with poor prognosis. British Journal of Cancer, 2014, 110, 2708-2715.	2.9	57
60	The molecular signature of impaired diabetic wound healing identifies serpinB3 as a healing biomarker. Diabetologia, 2014, 57, 1947-1956.	2.9	28
61	SERPINB3 protects from oxidative damage by chemotherapeutics through inhibition of mitochondrial respiratory complex I. Oncotarget, 2014, 5, 2418-2427.	0.8	57
62	Liver pro-oncogenic potential of SERPINB3. Oncoscience, 2014, 1, 502-503.	0.9	1
63	Role of SERPINB3 in hepatocellular carcinoma. Annals of Hepatology, 2014, 13, 722-7.	0.6	11
64	Serpins, Immunity and Autoimmunity: Old Molecules, New Functions. Clinical Reviews in Allergy and Immunology, 2013, 45, 267-280.	2.9	94
65	Specificity of squamous cell carcinoma antigen (SCCA)â€IgM detection in patients with HCV infection and rheumatoid factor seropositivity. Journal of Medical Virology, 2013, 85, 1005-1008.	2.5	12
66	SERPINB3 is associated with longer survival in transgenic mice. Scientific Reports, 2013, 3, 3056.	1.6	12
67	SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection. Experimental Biology and Medicine, 2012, 237, 793-802.	1.1	20
68	Increased Th1 immune response in SERPINB3 transgenic mice during acute liver failure. Experimental Biology and Medicine, 2012, 237, 1474-1482.	1.1	7
69	APCI1307K Mutations and Forkhead Box Gene (FOXO1A): Another Piece of an Interesting Correlation. International Journal of Biological Markers, 2012, 27, 13-19.	0.7	4
70	Over-expression of SERPINB3 in hepatoblastoma: A possible insight into the genesis of this tumour?. European Journal of Cancer, 2012, 48, 1219-1226.	1.3	43
71	IgM-Linked SerpinB3 and SerpinB4 in Sera of Patients with Chronic Liver Disease. PLoS ONE, 2012, 7, e40658.	1.1	22
72	Serum SCCA-IgM as a predictor of hepatocellular carcinoma in patients with liver cirrhosis. Open Journal of Gastroenterology, 2012, 02, 56-61.	0.1	14

#	Article	IF	Citations
73	Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of cirrhotic rats. Liver International, 2011, 31, 881-890.	1.9	21
74	Overexpression of SERPIN B3 promotes epithelial proliferation and lung fibrosis in mice. Laboratory Investigation, 2011, 91, 945-954.	1.7	31
75	Increased antiprotease activity of the SERPINB3 polymorphic variant SCCA-PD. Experimental Biology and Medicine, 2011, 236, 281-290.	1.1	17
76	SERPINB3 induces epithelialâ€“mesenchymal transition. Journal of Pathology, 2010, 221, 343-356.	2.1	77
77	SERPINB3 modulates TGF-Î² expression in chronic liver disease. Laboratory Investigation, 2010, 90, 1016-1023.	1.7	43
78	Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis. Clinical Chemistry and Laboratory Medicine, 2010, 48, 217-23.	1.4	11
79	Role of squamous cell carcinoma antigen-1 on liver cells after partial hepatectomy in transgenic mice. International Journal of Molecular Medicine, 2010, 25, 137-43.	1.8	19
80	SERPINB3, apoptosis and autoimmunity. Autoimmunity Reviews, 2009, 9, 108-112.	2.5	87
81	Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease. Digestive and Liver Disease, 2009, 41, 212-216.	0.4	10
82	Tumourâ€specific induction of immune complexes: DCPâ€IgM in hepatocellular carcinoma. European Journal of Clinical Investigation, 2008, 38, 571-577.	1.7	27
83	Monitoring SCCAâ€IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis. Journal of Viral Hepatitis, 2008, 15, 246-249.	1.0	35
84	Biological and clinical implications of HBV infection in peripheral blood mononuclear cells. Autoimmunity Reviews, 2008, 8, 13-17.	2.5	55
85	Squamous cell carcinoma antigen in human liver carcinogenesis. Journal of Clinical Pathology, 2008, 61, 445-447.	1.0	72
86	Overexpression of squamous cell carcinoma antigen in idiopathic pulmonary fibrosis: clinicopathological correlations. Thorax, 2008, 63, 795-802.	2.7	35
87	[471] SQUAMOUS CELL CARCINOMA ANTIGEN (SCCA) EXPRESSION AND CD27+ MEMORY B LYMPHOCYTES IN PATIENTS WITH CHRONIC HEPATITIS C. Journal of Hepatology, 2007, 46, S179.	1.8	1
88	Does HCV infection have a more favourable outcome in Tanzanian people?. Digestive and Liver Disease, 2007, 39, 891-892.	0.4	3
89	Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology, 2006, 43, 100-107.	3.6	191
90	Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. International Journal of Cancer, 2006, 119, 735-740.	2.3	73

#	Article	IF	Citations
91	Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease. World Journal of Gastroenterology, 2006, 12, 1706.	1.4	19
92	Virological Profiles in Hepatitis B Virus/Hepatitis C Virus Coinfected Patients under Interferon plus Ribavirin Therapy. Antiviral Therapy, 2006, 11, 931-934.	0.6	29
93	Extracellular matrix-enriched polymeric scaffolds as a substrate for hepatocyte cultures: in vitro and in vivo studies. Biomaterials, 2005, 26, 7038-7045.	5.7	75
94	Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer, 2005, 103, 2558-2565.	2.0	118
95	Profiles of HCV core protein and viremia in chronic Hepatitis C: possible protective role of core antigen in liver damage. Journal of Medical Virology, 2005, 76, 55-60.	2.5	17
96	Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites. Gut, 2005, 54, 1630-1636.	6.1	34
97	Improvement of Liver Cancer Detection with Simultaneous Assessment of Circulating Levels of Free Alpha-Fetoprotein (AFP) and Afp-Igm Complexes. International Journal of Biological Markers, 2004, 19, 155-159.	0.7	46
98	Hepatitis C virus quasispecies in the natural course of HCV-related disease in patients with haemophilia. Haemophilia, 2004, 10, 81-86.	1.0	6
99	Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma. British Journal of Cancer, 2004, 90, 833-837.	2.9	114
100	249 Expression of squamous cell carcinoma antigen in hepatocellular carcinoma and its precursors. Journal of Hepatology, 2004, 40, 78-79.	1.8	1
101	Surface expression of squamous cell carcinoma antigen (SCCA) can be increased by the preS1(21â€“47) sequence of hepatitis B virus. Journal of General Virology, 2004, 85, 621-624.	1.3	8
102	Parenchymal transforming growth factor beta-1: Its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral etiology. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 1302-1308.	1.4	34
103	Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection. European Journal of Gastroenterology and Hepatology, 2002, 14, 1377-1382.	0.8	12
104	High levels of soluble tumor necrosis factor superfamily receptors in patients with hepatitis C virus infection and lymphoproliferative disorders. Journal of Hepatology, 2001, 34, 723-729.	1.8	16
105	Cloning and Expression of a Novel Hepatitis B Virus-binding Protein from HepG2 Cells. Journal of Biological Chemistry, 2001, 276, 36613-36623.	1.6	69
106	Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut, 2001, 48, 110-115.	6.1	80
107	Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy. Journal of Viral Hepatitis, 2000, 7, 203-210.	1.0	19
108	Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology, 2000, 31, 1153-1159.	3.6	130

#	Article	IF	Citations
109	Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon. Gastroenterology, 2000, 119, 1649-1655.	0.6	60
110	The pattern of response to interferon alpha (Î±-IFN) predicts sustained response to a 6-month Î±-IFN and ribavirin retreatment for chronic hepatitis C. Journal of Hepatology, 2000, 33, 128-134.	1.8	30
111	Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. Journal of Viral Hepatitis, 1999, 6, 321-327.	1.0	10
112	Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-Î±. Journal of Viral Hepatitis, 1999, 6, 367-372.	1.0	24
113	Hepatitis C virus RNA profiles in chronically infected individuals: Do they relate to disease activity?. Hepatology, 1999, 29, 585-589.	3.6	76
114	Effect of Retreatment with Interferon Alone or Interferon plus Ribavirin on Hepatitis C Virus Quasispecies Diversification in Nonresponder Patients with Chronic Hepatitis C. Journal of Virology, 1999, 73, 7241-7247.	1.5	55
115	Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer, 1998, 83, 901-909.	2.0	124
116	Hepatitis C virus infection associated with human hepatocellular carcinoma. Cancer, 1998, 83, 1489-1494.	2.0	12
117	Characteristics of hepatitis C virus before and after interferon treatment in patients with ongoing viraemia but sustained biochemical response. , 1998, 54, 7-11.		3
118	Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut, 1998, 42, 856-860.	6.1	81
119	Coinfection by hepatitis B virus and hepatitis C virus. Antiviral Therapy, 1998, 3, 137-42.	0.6	40
120	Hepatitis C virus genotypes and liver disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1997, 19, 237-240.	1.3	16
121	Treatment of chronic hepatitis C with interferonâ€Î± by monitoring the response according to viraemia. Journal of Viral Hepatitis, 1997, 4, 107-112.	1.0	9
122	Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology, 1997, 113, 1654-1659.	0.6	44
123	In vivo translational efficiency of different hepatitis C virus 5â€²-UTRs. FEBS Letters, 1997, 411, 275-280.	1.3	42
124	Prevalence and Natural History of Hepatitis C Infection in Patients Cured of Childhood Leukemia. Blood, 1997, 90, 4628-4633.	0.6	131
125	Variables that influence response to different interferon schedules in chronic hepatitis C and predictive models. Journal of Viral Hepatitis, 1997, 4, 79-83.	1.0	3
126	A model to predict long-term sustained response to interferon therapy in chronic hepatitis C. Journal of Viral Hepatitis, 1997, 4, 193-197.	1.0	2

#	Article	IF	Citations
127	Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology, 1997, 25, 211-215.	3.6	128
128	Prevalence and Natural History of Hepatitis C Infection in Patients Cured of Childhood Leukemia. Blood, 1997, 90, 4628-4633.	0.6	4
129	Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology, 1997, 25, 211-215.	3.6	66
130	Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA. Journal of Hepatology, 1996, 24, 33-37.	1.8	39
131	Non-organ specific autoantibodies in children with chronic hepatitis C. Journal of Hepatology, 1996, 25, 614-620.	1.8	85
132	Hepatitis C virus genotypes in chronic hepatitis C of children. Journal of Viral Hepatitis, 1996, 3, 323-327.	1.0	9
133	Heterogeneity of hepatitis C virus. Bailliere's Clinical Gastroenterology, 1996, 10, 243-255.	0.9	5
134	Hepatitis C genotypes in patients with dual hepatitis B and C virus infection. Journal of Medical Virology, 1996, 48, 157-160.	2.5	46
135	Hepatitis C virus serotypes and liver pathology. Liver, 1996, 16, 353-357.	0.1	10
136	Hepatitis C genotypes in patients with dual hepatitis B and C virus infection. , 1996, 48, 157.		3
137	Persistent Hepatitis C Viremia Predicts Late Relapse after Sustained Response to Interferon-Î± in Chronic Hepatitis C. Annals of Internal Medicine, 1996, 124, 1058.	2.0	96
138	Hepatitis C virus genotypes and severity of chronic liver disease in haemophiliacs. British Journal of Haematology, 1995, 91, 708-713.	1.2	24
139	Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology, 1995, 22, 700-706.	3.6	175
140	Pilot study on the efficacy of intravenous natural ?-interferon therapy in Italian patients with chronic hepatitis C and relation to the HCV genotype. International Hepatology Communications, 1995, 3, 237-243.	0.7	9
141	Comparison of genotyping and serotyping methods for the identification of hepatitis C virus types. Journal of Virological Methods, 1995, 55, 303-307.	1.0	22
142	Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-Î±. Journal of Viral Hepatitis, 1995, 2, 91-96.	1.0	57
143	Distribution of three major hepatitis C virus genotypes in Italy. A multicentre study of 49 5 patients with chronic hepatitis C. Journal of Viral Hepatitis, 1995, 2, 33-38.	1.0	62
144	Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C*1. Hepatology, 1995, 22, 700-706.	3.6	102

#	Article	IF	Citations
145	HCV-associated liver cancer without cirrhosis. Lancet, The, 1995, 345, 413-415.	6.3	276
146	Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C.. Journal of Clinical Investigation, 1995, 95, 2067-2075.	3.9	109
147	Hepatitis C virus genotypes HCV-1a and HCV-1b: the clinical point of view. Journal of Infectious Diseases, 1995, 171, 760.	1.9	14
148	The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. Journal of Hepatology, 1995, 22, 38-41.	1.8	81
149	Evidence Against the Role of Hepatitis C Virus in Severe Liver Damage Occurring Early in the Course of Acute Leukemia in Children. Leukemia and Lymphoma, 1994, 13, 119-122.	0.6	7
150	Familial Cluster Of Hepatitis C Virus Type 1. Journal of Infectious Diseases, 1994, 170, 1042a-1043.	1.9	4
151	Childhood liver tumour tissue storage programme: A siop liver tumour study initiative. Medical and Pediatric Oncology, 1994, 22, 425-427.	1.0	2
152	A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. Journal of Hepatology, 1994, 21, 361-366.	1.8	13
153	Analysis of the hepatitis C virus genome in patients with anti-LKM-1 autoantibodies. Journal of Hepatology, 1994, 21, 273-276.	1.8	33
154	Genotypes of hepatitis C virus in Italian patients with chronic hepatitis C. International Hepatology Communications, 1994, 2, 105-112.	0.7	62
155	Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfaâ€2A interferon. Liver, 1994, 14, 257-264.	0.1	30
156	Outcome of Acute Hepatitis C and Role of Alpha Interferon Therapy. , 1994, , 604-606.		15
157	Patterns of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis and their relationship to viral replication and liver disease. Hepatology, 1993, 17, 179-182.	3.6	54
158	Cytokeratins patterns in childhood primary liver tumors. International Journal of Clinical and Laboratory Research, 1993, 23, 225-227.	1.0	9
159	Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology, 1993, 105, 1529-1533.	0.6	233
160	Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas. Oncogene, 1993, 8, 2303-6.	2.6	39
161	The preS1 domain of hepatitis B virus and IgA cross-react in their binding to the hepatocyte surface. Journal of General Virology, 1992, 73, 2041-2045.	1.3	42
162	Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet, The, 1992, 340, 697-698.	6.3	401

#	Article	IF	Citations
163	A randomized controlled trial of lymphoblastoid interferon-Î± in patients with chronic hepatitis B lacking HBeAg. Hepatology, 1992, 15, 584-589.	3.6	162
164	Therapy for chronic hepatitis B with lymphoblastoid interferon-Î± and levamisole. Hepatology, 1992, 16, 1115-1119.	3.6	28
165	Latent hepatitis B virus infection in childhood hepatocellular carcinoma analysis by polymerase chain reaction. Cancer, 1992, 69, 2731-2735.	2.0	30
166	Hepatitis B virus binds to peripheral blood mononuclear cells via the pre S1 protein. Journal of Hepatology, 1991, 12, 203-206.	1.8	35
167	HBV-DNA-related hepatocellular carcinoma occurring in childhood report of three cases. Digestive Diseases and Sciences, 1991, 36, 1143-1146.	1.1	28
168	The role of PreS1 in the interaction of hepatitis B virus with human hepatocytes. Hepatology, 1991, 14, 405-406.	3.6	6
169	Chronic type B hepatitis and primary hepatocellular carcinoma in children. European Journal of Pediatrics, 1991, 150, 685-685.	1.3	4
170	Hepatitis C Virus Infection in Chronic Hepatitis B Virus Carriers. Journal of Infectious Diseases, 1991, 163, 400-402.	1.9	139
171	Natural history and prognostic factors for chronic hepatitis type B.. Gut, 1991, 32, 294-298.	6.1	362
172	Interferon therapy of chronic delta hepatitis in patients cured of pediatric malignancies: possible harmful effect. Liver, 1991, 11, 255-259.	0.1	8
173	Nature and display of hepatitis B virus envelope proteins and the humoral immune response. Seminars in Immunopathology, 1990, 12, 5-23.	4.0	32
174	Fine specificity of human antibody response to the pres1 domain of hepatitis B virus. Hepatology, 1990, 12, 199-203.	3.6	26
175	Can primary cancer of the liver in western countries be prevented? Pediatric point of view. Medical and Pediatric Oncology, 1990, 18, 57-60.	1.0	5
176	Chronic persistent hepatitis type B can be a progressive disease when associated with sustained virus replication. Journal of Hepatology, 1990, 11, 29-33.	1.8	23
177	Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis. Liver, 1990, 10, 141-146.	0.1	31
178	Detection of hepatitis B virus DNA in serum by spot hybridization technique: Sensitivity and specificity of radiolabeled and biotin-labeled probes. Research in Clinic and Laboratory, 1990, 20, 29-35.	0.3	9
179	Serum levels of soluble interleukin-2 receptors in acute and chronic viral hepatitis. Digestive Diseases and Sciences, 1989, 34, 1559-1563.	1.1	23
180	Identification of an attachment site for human liver plasma membranes on hepatitis B virus particles. Virology, 1989, 173, 522-530.	1.1	145

#	Article	IF	Citations
181	Lymphoproliferative disease of granular lymphocytes in a patient with concomitant hepatitis B virus infection of CD4 lymphocytes. Journal of Clinical Immunology, 1989, 9, 401-408.	2.0	8
182	Serum HBV-DNA in anti-HBe positive patients detected by filter and liquid phase hybridization assays. Molecular and Cellular Probes, 1989, 3, 245-249.	0.9	4
183	Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B. Journal of Hepatology, 1989, 9, 331-337.	1.8	46
184	LIVER DISEASE IN ANTI-HBe POSITIVE CHRONIC HBsAg CARRIERS AND HEPATITIS C VIRUS. Lancet, The, 1989, 334, 797-798.	6.3	32
185	Hepatitis B virus DNA forms in the liver of chronically infected individuals. Journal of Hepatology, 1989, 9, 29-35.	1.8	6
186	Hepatitis B virus type 2 in Italian hemophiliacs. Transfusion, 1989, 29, 558-559.	0.8	1
187	Human liver plasma membranes contain receptors for the hepatitis B virus pre-S1 region and, via polymerized human serum albumin, for the pre-S2 region. Journal of Virology, 1989, 63, 1981-1988.	1.5	149
188	Hepatitis B core antigen in serum during acute hepatitis B. Journal of Medical Virology, 1988, 24, 361-367.	2.5	2
189	Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology, 1988, 8, 1651-1654.	3.6	138
190	Methods for the study of pre-S proteins of hepatitis B virus and their antibodies: pathogenetic and clinical implications. Research in Clinic and Laboratory, 1988, 18, 241-258.	0.3	6
191	Expression of preS1 and preS2 in the liver of chronic hepatitis B virus carriers. Journal of Hepatology, 1988, 7, 157-163.	1.8	15
192	ANTIBODY RESPONSE TO PRE-S2 AND HEPATITIS B VIRUS INDUCED LIVER DAMAGE. Lancet, The, 1988, 331, 1421-1424.	6.3	63
193	Cryptogenic Chronic Liver Disease and Serum or Liver Hepatitis B Virus Markers. Digestion, 1988, 39, 251-256.	1.2	9
194	Cell-Mediated Immunity to HBcAg in Chronic HBV Infection. American Journal of Clinical Pathology, 1987, 88, 494-498.	0.4	7
195	Hepatitis B virus (HBV)-DNA-positive hepatocellular carcinoma following hepatitis B virus infection in a child. Journal of Medical Virology, 1987, 23, 151-155.	2.5	12
196	Detection of hepatitis B virus DNA sequences in bone marrow of children with leukemia. Cancer, 1987, 59, 292-296.	2.0	21
197	Antibody to pre-S antigens in hepatitis B virus infection. Hepatology, 1987, 7, 207-208.	3.6	7
198	HBVâ€ÐNA sequences are rarely detected in the liver of patients with HBsAgâ€negative chronic active liver disease and with hepatocellular carcinoma in Italy. Liver, 1987, 7, 211-215.	0.1	17

#	Article	IF	Citations
199	Serum binding activity for polymerized human albumin due to antibodies detected by enzyme-linked immunosorbent assay in acute and chronic type B, A and NANB viral hepatitis. Research in Clinic and Laboratory, 1987, 17, 131-42.	0.3	1
200	Antibody to the hepatitis B virus receptor for polymerized albumin in acute infection and in hepatitis B vaccine recipients. Journal of Hepatology, 1986, 3, 393-398.	1.8	20
201	PRE-S2 ANTIBODIES IN HEPATITIS B. Lancet, The, 1986, 328, 1457-1458.	6.3	8
202	Levamisole therapy in chronic type B hepatitis. Gastroenterology, 1986, 91, 692-696.	0.6	36
203	Serum Hepatitis B Virus DNA in Acute Hepatitis Type B. Digestion, 1986, 34, 46-50.	1.2	13
204	Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology, 1986, 6, 167-171.	3.6	278
205	Changes in Serum Hepatitis B Virus (HBV) DNA Positivity in Chronic HBV Infection: Results of a Long-Term Follow-Up Study of 138 Patients. Journal of Infectious Diseases, 1986, 154, 562-569.	1.9	50
206	Hepatitis B core antigen (HBcAg) in serum of patients with chronic hepatitis B detected by a modified radioimmunoassay. Journal of Medical Virology, 1985, 17, 51-56.	2.5	6
207	Relationship between HBcAg in serum and liver and HBV replication in patients with HBsAg-positive chronic liver disease. Journal of Medical Virology, 1985, 17, 145-152.	2.5	24
208	An Antibody Which Precipitates Dane Particles in Acute Hepatitis Type B: Relation to Receptor Sites Which Bind Polymerized Human Serum Albumin on Virus Particles. Hepatology, 1984, 4, 220-226.	3.6	75
209	Polyalbumin receptors on hepatitis B virus and on 22 nm hepatitis B surface antigen (H BsAg)2 particles. Journal of Medical Virology, 1984, 13, 355-360.	2.5	12
210	Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 7708-7712.	3.3	205
211	Detection of hepatitis B virus DNA in mononuclear blood cells.. BMJ: British Medical Journal, 1984, 288, 1563-1566.	2.4	197
212	Receptors for polymerized human serum albumin on hepatitis B virus particles detected by radioimmunoassay: Changes in receptor activity in serum during acute and chronic infection. Journal of Virological Methods, 1983, 6, 151-159.	1.0	21
213	Cellular immunity to the hepatitis B virion in acute hepatitis type B. Clinical and Experimental Immunology, 1983, 53, 645-50.	1.1	20
214	Changes in hepatitis B virus DNA-polymerase activity in patients with chronic infection. Journal of Medical Virology, 1981, 8, 223-229.	2.5	28
215	SerpinB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease. Frontiers in Immunology, 0, 13, .	2.2	9